AngioDynamics has reported that its higher-margin vascular access devices and micro-catheter portfolio now account for over 55% of total revenues, up from 48% a year ago. This shift has driven a 200 basis-point expansion in operating margins in the most recent quarter, contributing to a 12% year-over-year increase in adjusted earnings per share. Management attributes the improvement to targeted sales efforts in interventional oncology and peripheral vascular businesses, where procedural volumes climbed by 15% globally.

Over the past four weeks, AngioDynamics’ stock has declined by 25%, triggering standard technical indicators that classify the share price as oversold. The Relative Strength Index (RSI) fell below 30 on three consecutive days, while trading volume spiked 40% above its 30-day average during sell-offs. Chart analysts point to a potential rebound as rapid declines often coincide with capitulation by short-term holders.

Following the stock’s pullback, Wall Street analysts have collectively raised full-year earnings estimates by an average of 7% over the past month. Of the 10 firms covering AngioDynamics, 8 have issued 'buy' or 'overweight' recommendations, up from 5 at the beginning of the quarter. The consensus 12-month price target implies a 30% upside from current levels, based on projected revenue growth of 10% for the fiscal year and operating margin expansion to 16%.